Lee_Cheryl_940x670Interim Chief Health Equity Officer, The Ohio State University Wexner Medical Center
Chair, Department of Urology
The Dorothy M. Davis Endowed Chair in Cancer Research
Vice President, OSU Physicians Inc. and Faculty Group Practice

Dr. Cheryl Lee was named chief health equity officer for the Ohio State Wexner Medical Center on an interim basis in July 2021. She’s also responsible for and serves as interim director for the Center for Health Equity as part of the university’s RAISE initiative. Additionally, Dr. Lee is chair of the Department of Urology, the Dorothy M. Davis Endowed Chair in Cancer Research and vice president of the OSU Physicians Inc. and Faculty Group Practice.

As chief health equity officer, Dr. Lee engages and collaborates with faculty, staff and learners across the medical center, the seven health science colleges and the broader university – as well as with community organizations, nonprofit organizations, government and other external stakeholders – to reduce or eliminate disparities in health and the determinants that adversely impact marginalized groups in the communities the Wexner Medical Center serves, with the goal of fostering more equitable care and health outcomes.

Dr. Lee was recruited to The Ohio State University in 2016 to lead the Department of Urology from the University of Michigan, where she’d been a faculty member for 16 years, rising in ranks to Professor with Tenure, and was the inaugural Dr. Robert H. and Eva M. Moyad Research Professor.

Active in the education of students, residents and practicing urologists, Dr. Lee has directed or been a faculty member of a postgraduate course at the annual meeting of the American Urologic Association for more than a decade and has been a leader in its educational service through her roles on its Education Council and the American Urologic Association Update Editorial Board. She’s played a key role in the board certification of urologists in America through her service on the American Board of Urology/American Urologic Association Examination Committee, the American Board of Urology Oral Board Examination Committee and the Oncology Knowledge Assessment Test Committee of the Society of Urologic Oncology. As a trustee of the American Board of Urology, she helps to shape standards for the practice of urology within the United States.

Dr. Lee’s current research interest involves the use of artificial intelligence to improve bladder cancer staging. She’s authored more than 175 publications, editorials and book chapters and has participated in more than 60 clinical trials. She provides scientific review for the National Cancer Institute and medical journals such as JAMA Surgery. She helps to set research and practice standards in urology through her current service on the AUA Science and Quality Council, and was also recently elected to the American Association of Genitourinary Surgeons.

Dr. Lee has served the Bladder Cancer Advocacy Network as the president of the Scientific Advisory Board, as a current member of its Board of Directors and as a past chairman of the Bladder Cancer Think Tank. She’s a past member of the Society of Urologic Oncology’s board of directors and currently serves as its liaison to the American Joint Committee on Cancer. She also previously served the board of directors of the American Cancer Society, Lakeshore Division.

Dr. Lee earned her medical degree from the Albany Medical College and completed a urology residency at the University of Michigan Hospitals and a urologic oncology fellowship at the Memorial Sloan Kettering Cancer Center.